• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Past Event

New Business Models for Antibiotics

Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance. Professor Kevin Outterson is working at Chatham House on evaluating…

Date

31/03/23 12:22 am

Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance. Professor Kevin Outterson is working at Chatham House on evaluating alternatives that will promote both innovation and long-term sustainability of this valuable resource.

Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance. Professor Kevin Outterson is working at Chatham House on evaluating alternatives that will promote both innovation and long-term sustainability of this valuable resource.

A Professor of Law at Boston University, Professor Outterson is a Visiting Fellow at the Royal Institute of International Affairs at Chatham House. His research interests include global pharmaceutical markets, finance and organisation of health care systems, and antimicrobial resistance, particularly those threatened by the development of resistance. He leads an interdisciplinary project on the legal ecology of antimicrobial resistance, is a faculty affiliate at the Harvard Center for Communicable Disease Dynamics, and an appointed member of the Antimicrobial Resistance Working Group at the CDC.

Professor Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program. He serves as the editor-in-chief of the Journal of Law, Medicine & Ethics and is faculty co-advisor to the American Journal of Law & Medicine. Before teaching, Professor Outterson was a partner at two major US law firms.

The slide presentation for this seminar is available on OHE's SlideShare site: http://www.slideshare.net/OHENews/new-business-model-for-antibiotics-outterson-april-2014

Related Events

WebsiteImage
  • Past Event
  • Sponsored Webinar
  • March 2023

Informal Caring Burden in HTA Series: Webinar 3 – Capturing carer burden in HTA: what is the future?

Read more
WebsiteImage
  • Past Event
  • Sponsored Webinar
  • February 2023

Informal Caring Burden in HTA Series: Webinar 2 – How is carer burden captured in HTA, and what are some of the existing challenges?

Read more
WebsiteImage
  • Past Event
  • Sponsored Webinar
  • February 2023

Informal Caring Burden in HTA Series: Webinar 1 – What is carer burden and why is it important in HTA?

Read more
ValueofVacc_JoinedImage
  • Past Event
  • OHE Webinar
  • January 2023

The Value of Vaccines and Taskforces

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!